139 related articles for article (PubMed ID: 32403147)
21. Effects of growth hormone-releasing hormone and its agonistic and antagonistic analogs in cancer and non-cancerous cell lines.
Barabutis N; Siejka A; Schally AV
Int J Oncol; 2010 May; 36(5):1285-9. PubMed ID: 20372804
[TBL] [Abstract][Full Text] [Related]
22. Growth hormone-releasing hormone antagonists counteract hydrogen peroxide - induced paracellular hyperpermeability in endothelial cells.
Barabutis N; Siejka A; Akhter MS
Growth Horm IGF Res; 2023; 69-70():101534. PubMed ID: 37210756
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
Seitz S; Hohla F; Schally AV; Moder A; Engel JB; Horn F; Varga J; Zarandi M; Ortmann O; Köster F; Buchholz S
Oncol Rep; 2008 Nov; 20(5):1289-94. PubMed ID: 18949435
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.
Rick FG; Schally AV; Block NL; Abi-Chaker A; Krishan A; Szalontay L
Prostate; 2013 Jun; 73(8):873-83. PubMed ID: 23280565
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of experimental small-cell and non-small-cell lung cancers by novel antagonists of growth hormone-releasing hormone.
Wang H; Zhang X; Vidaurre I; Cai R; Sha W; Schally AV
Int J Cancer; 2018 Jun; 142(11):2394-2404. PubMed ID: 29435973
[TBL] [Abstract][Full Text] [Related]
26. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
[TBL] [Abstract][Full Text] [Related]
27. GHRH antagonists support lung endothelial barrier function.
Uddin MA; Akhter MS; Singh SS; Kubra KT; Schally AV; Jois S; Barabutis N
Tissue Barriers; 2019; 7(4):1669989. PubMed ID: 31578921
[TBL] [Abstract][Full Text] [Related]
28. GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells.
Hohla F; Buchholz S; Schally AV; Seitz S; Rick FG; Szalontay L; Varga JL; Zarandi M; Halmos G; Vidaurre I; Krishan A; Kurtoglu M; Chandna S; Aigner E; Datz C
Cell Cycle; 2009 Oct; 8(19):3149-56. PubMed ID: 19755849
[TBL] [Abstract][Full Text] [Related]
29. GHRH antagonist MZ-5-156 increases the expression of AMPK in A549 lung cancer cells.
Siejka A; Barabutis N; Schally AV
Cell Cycle; 2011 Nov; 10(21):3714-8. PubMed ID: 22041656
[TBL] [Abstract][Full Text] [Related]
30. A method for evaluation of activity of antagonistic analogs of growth hormone-releasing hormone in a superfusion system.
Rekasi Z; Schally AV
Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2146-9. PubMed ID: 8460121
[TBL] [Abstract][Full Text] [Related]
31. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory effects of GHRH antagonists on human GH-secreting adenoma tissue.
Szalontay L; Benveniste RJ; Schally AV; Vidaurre I; Nadji M; Zarandi M; Block NL; Kovacs M
Neuroendocrinology; 2012; 96(1):81-8. PubMed ID: 22377963
[TBL] [Abstract][Full Text] [Related]
33. Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity.
Cai R; Zhang X; Wang H; Cui T; Halmos G; Sha W; He J; Popovics P; Vidaurre I; Zhang C; Mirsaeidi M; Schally AV
Peptides; 2022 Apr; 150():170716. PubMed ID: 34952135
[TBL] [Abstract][Full Text] [Related]
34. Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer.
Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Sánchez-Chapado M; Prieto JC; Bajo AM
Oncotarget; 2016 Aug; 7(32):52195-52206. PubMed ID: 27448980
[TBL] [Abstract][Full Text] [Related]
35. Growth hormone-releasing hormone antagonistic analog MIA-690 stimulates food intake in mice.
Recinella L; Chiavaroli A; Orlando G; Ferrante C; Gesmundo I; Granata R; Cai R; Sha W; Schally AV; Brunetti L; Leone S
Peptides; 2021 Aug; 142():170582. PubMed ID: 34051291
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro.
Csernus VJ; Schally AV; Kiaris H; Armatis P
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):3098-103. PubMed ID: 10077643
[TBL] [Abstract][Full Text] [Related]
37. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
38. Essential role of p21/waf1 in the mediation of the anti-proliferative effects of GHRH antagonist JMR-132.
Volakaki AA; Lafkas D; Kassi E; Schally AV; Papavassiliou AG; Kiaris H
J Mol Endocrinol; 2008 Nov; 41(5):389-92. PubMed ID: 18765563
[TBL] [Abstract][Full Text] [Related]
39. Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH.
Schally AV; Wang H; He J; Cai R; Sha W; Popovics P; Perez R; Vidaurre I; Zhang X
Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12028-12033. PubMed ID: 30373845
[TBL] [Abstract][Full Text] [Related]
40. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
Chatzistamou I; Schally AV; Varga JL; Groot K; Armatis P; Busto R; Halmos G
J Clin Endocrinol Metab; 2001 May; 86(5):2144-52. PubMed ID: 11344219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
